Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
|||||||
| Revenues: | ||||||||||
| Total revenues, net | $ 353,171 | $ 120,700 | $ 791,362 | $ 347,898 | ||||||
| Cost of revenues: | ||||||||||
| Total cost of revenues | 20,450 | 6,563 | 45,435 | 12,855 | ||||||
| Research and development | 143,506 | 112,874 | 419,590 | 335,536 | ||||||
| Selling, general and administrative | 200,854 | 137,621 | 551,011 | 373,140 | ||||||
| Restructuring, impairment, and related charges | 0 | 8,841 | 0 | 10,216 | ||||||
| Total operating costs and expenses | 364,810 | 265,899 | 1,016,036 | 731,747 | ||||||
| Loss from operations | (11,639) | (145,199) | (224,674) | (383,849) | ||||||
| Other income (expense), net: | ||||||||||
| Interest income | 13,105 | 6,239 | 26,010 | 15,522 | ||||||
| Interest expense | (13,255) | (11,739) | (39,475) | (41,467) | ||||||
| Noncash interest expense on deferred royalty obligations | [1] | (42,282) | (36,410) | (123,500) | [2] | (86,460) | [2] | |||
| Net loss from equity method investments | (7,312) | (15,834) | (32,030) | (51,579) | ||||||
| Loss on extinguishment of debt | 0 | 0 | 0 | (21,155) | ||||||
| Other income, net | 2,116 | 16,461 | 11,956 | 31,240 | ||||||
| Total other expense, net | (47,628) | (41,283) | (157,039) | (153,899) | ||||||
| Loss before income taxes | (59,267) | (186,482) | (381,713) | (537,748) | ||||||
| Provision for (benefit from) income taxes | 1,229 | (1,545) | 1,229 | 555 | ||||||
| Net loss | (60,496) | (184,937) | (382,942) | (538,303) | ||||||
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 3,786 | 2,194 | 9,973 | 6,235 | ||||||
| Net loss attributable to BridgeBio | (56,710) | (182,743) | (372,969) | (532,068) | ||||||
| Preferred stock dividends and accretion | 26,293 | 0 | 26,293 | 0 | ||||||
| Net loss attributable to common stockholders of BridgeBio | $ (83,003) | $ (182,743) | $ (399,262) | $ (532,068) | ||||||
| Net loss per share attributable to common stockholders of BridgeBio, basic (in dollars per share) | $ (0.42) | $ (0.95) | $ (2.04) | $ (2.79) | ||||||
| Net loss per share attributable to common stockholders of BridgeBio, diluted (in dollars per share) | $ (0.42) | $ (0.95) | $ (2.04) | $ (2.79) | ||||||
| Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic (in shares) | 196,029,851 | 191,854,152 | 195,539,752 | 190,845,133 | ||||||
| Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, diluted (in shares) | 196,029,851 | 191,854,152 | 195,539,752 | 190,845,133 | ||||||
| Net product revenue | ||||||||||
| Revenues: | ||||||||||
| Total revenues, net | $ 253,346 | $ 108,111 | $ 656,382 | $ 216,351 | ||||||
| Cost of revenues: | ||||||||||
| Total cost of revenues | 12,317 | 4,028 | 30,577 | 8,910 | ||||||
| License and services revenue | ||||||||||
| Revenues: | ||||||||||
| Total revenues, net | 79,314 | 8,311 | 89,537 | 125,441 | ||||||
| Royalty revenue | ||||||||||
| Revenues: | ||||||||||
| Total revenues, net | 20,511 | 4,278 | 45,443 | 6,106 | ||||||
| Cost of license, services, and royalty revenue | ||||||||||
| Cost of revenues: | ||||||||||
| Total cost of revenues | $ 8,133 | $ 2,535 | $ 14,858 | $ 3,945 | ||||||
| ||||||||||
| X | ||||||||||
- Definition Noncash Interest Expense On Deferred Royalty Obligations No definition available.
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of preferred stock dividends and adjustments classified as other. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of restructuring charges, remediation cost, and asset impairment loss. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|